Home/ Stocks/ CLRB

Cellectar Biosciences INC NEW

CLRB XNAS

$2.57 +0.05 (+1.98%) ▲ 15-min delayed

Open

$2.52

High

$2.59

Low

$2.49

Volume

16.1K

Market Cap

$20.14M

About Cellectar Biosciences INC NEW

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 11 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-5,653,946	$-1.33
FY 2025	$0	$-21,791,037	$-8.35
Q3 2025	$0	$-4,443,877	$-1.41
Q2 2025	$0	$-5,447,911	$-3.39

Related Market News

No specific coverage for CLRB yet. Check out our latest market news or earnings calendar.

Get CLRB Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Cellectar Biosciences INC NEW.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.